Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with
advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20 …

The position of immunotherapy as a pillar of systemic cancer treatment has been firmly
established over the past decade. Immune checkpoint inhibitors are a welcome option for …

Hepatocellular carcinoma (HCC) is the most common liver cancer with high morbidity and
mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase …

The discovery of the immune checkpoint mechanism has contributed greatly to recent
advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody …

Introduction Immunotherapy has recently taken on an extremely important role in medical
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …

Simple Summary Immune checkpoint inhibitors represent a promising treatment choice in
many kind of tumours, including hepatocellular carcinoma (HCC). In this review, we provide …

Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell
death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte …

Hepatocellular carcinoma (HCC) is usually diagnosed in an advanced stage and has
become the second deadliest type of cancer worldwide. The systemic treatment of advanced …

Hepatocellular carcinoma (HCC) is one of most common cancers and the fourth leading
cause of death worldwide. Commonly, HCC development occurs in a liver that is severely …